Subsequent studies using peptide-HLA multimers to define SARS-CoV-2-specific T cell responses provide now enough evidence to show that robust CD4+ and CD8+ T cells can be elicited during BNT162b2 mRNA COVID-19 vaccination. This evidence concerns the gene CD4 and COVID-19.